Anixa Biosciences
ANIXAnixa Biosciences is a clinical-stage biotechnology company focused on developing novel therapies and vaccines to address significant unmet needs in oncology.
Earnings
Next report
Jan 11, 2027 (in 2 months)Competitors
By market cap
Profile
Anixa Biosciences is a clinical-stage biotechnology company focused on developing novel therapies and vaccines to address significant unmet needs in oncology. The company's portfolio includes a chimeric endocrine receptor-T cell (CER-T) therapy for solid tumors and a suite of prophylactic cancer vaccines targeting retired proteins. Anixa operates through a capital-light model, leveraging strategic collaborations with leading research institutions to advance its pipeline through clinical trials.
Anixa is an early-stage innovator in the solid tumor CAR-T and prophylactic cancer vaccine space, relying on high-profile academic partnerships to compete with larger biopharmaceutical entities.
FAQ
- What is Anixa Biosciences's market cap?
- Anixa Biosciences (ANIX) has a market capitalization of $114.7M and trades on NASDAQ.
- Who are Anixa Biosciences's competitors?
- Anixa Biosciences's key competitors include Greenwich LifeSciences, Inc., Immunome, Inc., Bristol-Myers Squibb, and others. These companies compete in similar markets and product categories.
- Who does Anixa Biosciences partner with?
- Anixa Biosciences's notable partners include The Wistar Institute, H. Lee Moffitt Cancer Center and Research Institute, The Cleveland Clinic Foundation, and others.
- What subsidiaries does Anixa Biosciences have?
- Anixa Biosciences's subsidiaries include Certainty Therapeutics, Inc..
- Where is Anixa Biosciences headquartered?
- Anixa Biosciences is headquartered in United States of America and employs approximately 6 people. It has been publicly traded since 1983.